{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:42Z","timestamp":1783977222106,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Secukinumab has been shown effective for psoriatic arthritis (PsA) and axial spondylarthritis (AxSpA) in randomized trials. The aim of this study was to analyze baseline patient and disease characteristics associated with a better retention rate of secukinumab under real-world conditions.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> Real-life, prospective multicenter observational study involving 138 patients, 61 PsA and 77 AxSpA, who were analyzed at baseline, 6, 12 months and subsequently every year after starting secukinumab regardless of the line of treatment. Demographics and disease characteristics, measures of activity, secukinumab use, and adverse events were collected. Drug survival was analyzed using Kaplan-Meier curves and factors associated with discontinuation were evaluated using Cox regression. The machine-learning J48 decision tree classifier was also applied.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> During the 1st year of treatment, 75% of patients persisted with secukinumab, but accrued 71% (<jats:italic>n<\/jats:italic> = 32) in total losses (<jats:italic>n<\/jats:italic> = 45). The backward stepwise (Wald) method selected diagnosis, obesity, and gender as relevant variables, the latter when analyzing the interactions. At 1 year of follow-up, the Cox model showed the best retention rate in the groups of AxSpa women (95%, 95% CI 93\u201397%) and PsA men (89%, 95% CI 84\u201393%), with the worst retention in PsA women (66%, 95% CI 54\u201379%). The J48 predicted secukinumab retention with an accuracy of 77.2%. No unexpected safety issues were observed.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Secukinumab shows the best retention rate at 1 year of treatment in AxSpA women and in PsA men, independently of factors such as the time of disease evolution, the line of treatment or the initial dose of the drug.<\/jats:p>","DOI":"10.3389\/fmed.2021.815881","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T05:20:33Z","timestamp":1642051233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Alicia","family":"Garc\u00eda-Dorta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Le\u00f3n-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodr\u00edguez-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gonz\u00e1lez-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Vanesa","family":"Hern\u00e1ndez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"D\u00edaz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/03009742.2019.1669704","article-title":"Prevalence of ankylosing spondylitis in Spain: EPISER2016 Study","volume":"49","author":"Quilis","year":"2020","journal-title":"Scand J Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0234556","DOI":"10.1371\/journal.pone.0234556","article-title":"Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study","volume":"15","author":"Romero Perez","year":"2020","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/rheumatology\/keu398","article-title":"Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study","volume":"54","author":"Giacomelli","year":"2015","journal-title":"Rheumatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/rheumatology\/kew467","article-title":"Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice","volume":"56","author":"Aaltonen","year":"2017","journal-title":"Rheumatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/rmdopen-2020-001280","article-title":"Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration","volume":"6","author":"Michelsen","year":"2020","journal-title":"RMD Open."},{"key":"B14","doi-asserted-by":"publisher","first-page":"679009","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in Cantabria and ASTURias study","volume":"8","author":"Alonso","year":"2021","journal-title":"Front Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","article-title":"One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study","volume":"20","author":"Chimenti","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"B16","article-title":"Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis","author":"Eviatar","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1093\/rheumatology\/keab245","article-title":"Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure","volume":"60","author":"Ki Min","year":"2021","journal-title":"Rheumatology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/rheumatology\/keaa825","article-title":"Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis","volume":"60","author":"Lindstrom","year":"2021","journal-title":"Rheumatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3899\/jrheum.181089","article-title":"Endorsement of the 66\/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis Workshop Report","volume":"46","author":"Duarte-Garcia","year":"2019","journal-title":"J Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B23","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol."},{"key":"B24","unstructured":"MotulskyHJ\n          GraphPad Curve Fitting Guide"},{"key":"B25","volume-title":"C4.5: Programs for Machine Learning","author":"Quinlan","year":"1993"},{"key":"B26","unstructured":"3540\n            JagtapSB\n            KodgeBG\n          25916548SingaporeInternational Conference in Emerging Trends in Science, Technology and ManagementCensus Data Mining and Data Analysis using WEKA2013"},{"key":"B27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6983272","DOI":"10.1155\/2020\/6983272","article-title":"Long-term effectiveness of secukinumab in patients with axial spondyloarthritis","volume":"2020","author":"Gentileschi","year":"2020","journal-title":"Mediators Inflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fmed.2020.00288","article-title":"Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis","volume":"7","author":"Klavdianou","year":"2020","journal-title":"Front Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MEG.0000000000001008","article-title":"Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71,806 patients","volume":"30","author":"Saad","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5120\/ijca2017913660","article-title":"Analysis of various decision tree algorisms from classification in data mining","volume":"163","author":"Gupta","year":"2017","journal-title":"Int J Comp Appli."},{"key":"B34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fimmu.2014.00576","article-title":"Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases)","volume":"5","author":"Gremese","year":"2014","journal-title":"Front Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/annrheumdis-2012-201632","article-title":"The link between obesity and psoriatic arthritis","volume":"71","author":"Canete","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1055\/s-0031-1287783","article-title":"Systemic blockade of TNF-alpha does not improve insulin resistance in humans","volume":"43","author":"Ferraz-Amaro","year":"2011","journal-title":"Horm Metab Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.autrev.2016.01.010","article-title":"Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy","volume":"15","author":"Iannone","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"30107","DOI":"10.3390\/metabo10030107","article-title":"The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition","volume":"10","author":"Toussirot","year":"2020","journal-title":"Metabolites."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217251","article-title":"Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index","author":"Pantano","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1046\/j.1469-1809.2003.00015.x","article-title":"A predominant European ancestry of paternal lineages from Canary Islanders","volume":"67","author":"Flores","year":"2003","journal-title":"Ann Hum Genet."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.815881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T05:20:40Z","timestamp":1642051240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.815881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":42,"alternative-id":["10.3389\/fmed.2021.815881"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.815881","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"article-number":"815881"}}